{'52WeekChange': -0.105263114,
 'SandP52WeekChange': None,
 'address1': '3033 Science Park Road',
 'address2': 'Suite 220',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 19.25,
 'askSize': 900,
 'averageDailyVolume10Day': 325962,
 'averageVolume': 768220,
 'averageVolume10days': 325962,
 'beta': 2.29202,
 'beta3Year': None,
 'bid': 16.6,
 'bidSize': 1200,
 'bookValue': 4.473,
 'category': None,
 'circulatingSupply': None,
 'city': 'San Diego',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 17.27,
 'dayLow': 16.625,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 580653760,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 17.365856,
 'fiftyTwoWeekHigh': 20,
 'fiftyTwoWeekLow': 6.35,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 40463167,
 'forwardEps': -1.96,
 'forwardPE': -8.72449,
 'fromCurrency': None,
 'fullTimeEmployees': 62,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.13022,
 'heldPercentInstitutions': 0.73713994,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/kuraoncology.com',
 'longBusinessSummary': 'Kura Oncology, Inc., a clinical-stage '
                        'biopharmaceutical company, develops medicines for the '
                        'treatment of cancer. Its pipeline consists of small '
                        'molecule product candidates that target cancer. The '
                        "company's lead product candidate is Tipifarnib, an "
                        'orally bioavailable inhibitor of farnesyl transferase '
                        'that is in Phase II clinical trials for the treatment '
                        'of solid tumors, peripheral T-cell lymphomas, and '
                        'other hematologic malignancies. It is also developing '
                        'KO-947, a small molecule inhibitor of extracellular '
                        'signal related kinase used for the treatment of '
                        'patients with tumors that have dysregulated activity '
                        'due to mutations or other mechanisms in the '
                        'mitogen-activated protein kinase pathway; and KO-539, '
                        'a small molecule inhibitor of the menin-mixed lineage '
                        'leukemia protein-protein interaction. Kura Oncology, '
                        'Inc. was founded in 2014 and is headquartered in San '
                        'Diego, California.',
 'longName': 'Kura Oncology, Inc.',
 'market': 'us_market',
 'marketCap': 955919104,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_282774456',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -68410000,
 'nextFiscalYearEnd': 1640908800,
 'open': 17.07,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.48,
 'phone': '858 500 8800',
 'previousClose': 17.34,
 'priceHint': 2,
 'priceToBook': 3.8229377,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 17.27,
 'regularMarketDayLow': 16.625,
 'regularMarketOpen': 17.07,
 'regularMarketPreviousClose': 17.34,
 'regularMarketPrice': 17.07,
 'regularMarketVolume': 277806,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 55901700,
 'sharesPercentSharesOut': 0.0682,
 'sharesShort': 3813570,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2756856,
 'shortName': 'Kura Oncology, Inc.',
 'shortPercentOfFloat': 0.081599995,
 'shortRatio': 5.38,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'KURA',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.563,
 'twoHundredDayAverage': 13.478705,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'd959d119-9140-35ab-8205-a916e1fac9db',
 'volume': 277806,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.kuraoncology.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '92121'}